Skip to content
Nexium, Nexium control(esomeprazole)
Nexium, Vimovo (esomeprazole) is a small molecule pharmaceutical. Esomeprazole was first approved as Nexium on 2001-02-20. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. It has been approved in Europe to treat gastroesophageal reflux. The pharmaceutical is active against potassium-transporting ATPase alpha chain 1.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Nexium (generic drugs available since 2013-03-18)
Combinations
Vimovo (generic drugs available since 2013-03-18)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Esomeprazole magnesium
Tradename
Company
Number
Date
Products
NEXIUMAstraZenecaN-021153 RX2001-02-20
2 products, RLD, RS
NEXIUMAstraZenecaN-021957 RX2006-10-20
4 products, RLD, RS
NEXIUMAstraZenecaN-022101 RX2008-02-27
1 products, RLD
NEXIUM 24HRAstraZenecaN-204655 OTC2014-03-28
1 products, RLD, RS
NEXIUM 24HRAstraZenecaN-207920 OTC2015-11-23
1 products, RLD, RS
Show 1 discontinued
Esomeprazole magnesium
+
Naproxen
Tradename
Company
Number
Date
Products
VIMOVOHorizon PharmaceuticalN-022511 RX2010-04-30
2 products, RLD
Esomeprazole sodium
Tradename
Company
Number
Date
Products
NEXIUM IVAstraZenecaN-021689 RX2005-03-31
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nexiumNew Drug Application2022-03-04
vimovoNew Drug Application2021-05-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
duodenal ulcerEFO_0004607D004381K26
esophagitisHP_0100633D004941K20
gastroesophageal refluxEFO_0003948D005764K21
heartburnD006356R12
helicobacter infectionsEFO_1000961D016481
zollinger-ellison syndromeD015043E16.4
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Esomeprazole Magnesium, Esomeprazole Magnesium, Dexcel
100764942036-12-08DP
108354882036-12-08DP
Esomeprazole Magnesium / Naproxen, Vimovo, Horizon
89456212031-10-17U-1661
92206982031-03-10U-1781
93932082029-09-03U-1781
ATC Codes
A: Alimentary tract and metabolism drugs
A02: Drugs for acid related disorders
A02B: Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC: Proton pump inhibitors for peptic ulcer and gord
A02BC05: Esomeprazole
A02BD: Combinations for eradication of helicobacter pylori
A02BD06: Esomeprazole, amoxicillin and clarithromycin
M: Musculo-skeletal system drugs
M01: Antiinflammatory and antirheumatic products
M01A: Antiinflammatory and antirheumatic products, non-steroids
M01AE: Propionic acid derivatives, antiinflammatory and antirheumatic products
M01AE52: Naproxen and esomeprazole
HCPCS
No data
Clinical
Clinical Trials
365 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastroesophageal refluxD005764EFO_0003948K2181321311282
InfectionsD007239EFO_000054412321146
Healthy volunteers/patients3511541
DyspepsiaD004415EFO_0008533K3026410121
Stomach ulcerD013276K25122115
EsophagitisD004941HP_0100633K20127515
GastritisD005756EFO_0000217K29.72135314
Peptic ulcerD010437HP_0004398K273126113
HeartburnD006356R12113711
Barrett esophagusD001471EFO_0000280K22.711327
Show 30 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pre-eclampsiaD011225EFO_0000668O1411225
Duodenal ulcerD004381EFO_0004607K26314
AsthmaD001249EFO_0000270J45213
Gastrointestinal hemorrhageD006471K92.2123
Gastrointestinal diseasesD005767123
Eosinophilic esophagitisD057765EFO_0004232K20.01112
Esophageal neoplasmsD004938C15112
ArthritisD001168EFO_0005856M05-M14112
Type 2 diabetes mellitusD003924EFO_0001360E11112
HemorrhageD006470MP_0001914R5822
Show 15 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autism spectrum disorderD000067877F84.0112
Replacement arthroplasty kneeD01964511
NeuralgiaD009437EFO_000943011
Autistic disorderD001321EFO_0003758F84.011
Deglutition disordersD003680HP_0002015R13.111
Cystic fibrosisD003550EFO_0000390E8411
Gram-negative bacterial infectionsD01690511
Tooth erosionD014077K03.2111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharmacokineticsD010599415
Therapeutic equivalencyD01381022
NeoplasmsD009369C8022
Breast neoplasmsD001943EFO_0003869C5011
Pulmonary hypertensionD006976EFO_0001361I27.2011
Pulmonary arterial hypertensionD00008102911
Chronic hepatitis bD019694EFO_0004197B18.111
LymphomaD008223C85.911
HomeostasisD00670611
Chronic pancreatitisD050500EFO_0000342K86.111
Show 4 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PyloromyotomyD00007488211
Calcium metabolism disordersD002128EFO_0005769E83.511
RadiotherapyD01187811
MortalityD009026EFO_000435211
HemostasisD00648711
Vasomotor rhinitisD012223EFO_0007533J30.011
Esophageal achalasiaD004931HP_0002571K22.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameESOMEPRAZOLE
INNesomeprazole
Description
Esomeprazole is a 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole that has S configuration at the sulfur atom. An inhibitor of gastric acid secretion, it is used (generally as its sodium or magnesium salt) for the treatment of gastro-oesophageal reflux disease, dyspepsia, peptic ulcer disease, and Zollinger-Ellison syndrome. It has a role as a histamine antagonist, an EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor, an anti-ulcer drug and an EC 1.4.3.4 (monoamine oxidase) inhibitor. It is a conjugate acid of an esomeprazole(1-). It is an enantiomer of a (R)-omeprazole.
Classification
Small molecule
Drug classantiulcer agents (benzimidazole derivatives)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1
Identifiers
PDB
CAS-ID119141-88-7
RxCUI283742
ChEMBL IDCHEMBL1201320
ChEBI ID50275
PubChem CID9568614
DrugBankDB00736
UNII IDN3PA6559FT (ChemIDplus, GSRS)
Target
Agency Approved
ATP4A
ATP4A
Organism
Homo sapiens
Gene name
ATP4A
Gene synonyms
NCBI Gene ID
Protein name
potassium-transporting ATPase alpha chain 1
Protein synonyms
ATPase H+/K+ transporting alpha subunit, ATPase, H+/K+ exchanging, alpha polypeptide, ATPase, H+/K+ transporting, alpha polypeptide, epididymis secretory sperm binding protein, Gastric H(+)/K(+) ATPase subunit alpha, gastric H+/K+ ATPase alpha subunit, gastric H,K-ATPase catalytic subunit, gastric hydrogen-potassium ATPase, Proton pump
Uniprot ID
Mouse ortholog
Atp4a (11944)
potassium-transporting ATPase alpha chain 1 (Q9CV46)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Vimovo - Horizon Therapeutics Public
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Nexium - AstraZeneca
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,658 documents
View more details
Safety
Black-box Warning
Black-box warning for: Vimovo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,145 adverse events reported
View more details